

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF ONESOURCE SPECIALTY PHARMA LIMITED (FORMERLY KNOWN AS STELIS BIOPHARMA LIMITED)

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **OneSource Specialty Pharma Limited (formerly known as Stelis Biopharma Limited)** ("the Company"), for the quarter and nine months ended December 31, 2025 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **DELOITTE HASKINS & SELLS**
Chartered Accountants
(Firm's Registration No. 008072S)

Sandeep
Ramesh Kukreja

Digitally signed by
Sandeep Ramesh Kukreja
Date: 2026.01.23 19:18:28
+05'30'

Sandeep Kukreja
Partner
(Membership No. 220411)
(UDIN:26220411LMZUMB9804)

Place: Bengaluru
Date: January 23, 2026

OneSource Specialty Pharma Limited (formerly known as Stelis Biopharma Limited)
Registered Office : Unit no. 902, "Cyber One" situated at Plot no.-4 & 6, Sector 30A, Vashi, Navi Mumbai - 400703
Corporate Office : Star 1, Opp IIM Bangalore, Bilekahalli, Bannerghatta Road, Bangalore - 560076, India
CIN: L74140MH2007PLC432497, Website : <https://www.onesourcecdmo.com>, Mail: info@onesourcecdmo.com

Statement of Unaudited Standalone Financial Results for the quarter and nine months ended December 31, 2025

Rs. in Million, except per share data

| Sl No | Particulars | Quarter ended | | | Nine months ended | | Year ended |
|-----------|--|----------------------------------|-----------------------------------|----------------------------------|----------------------------------|----------------------------------|-----------------------------|
| | | December 31, 2025 (Unaudited) | September 30, 2025 (Unaudited) | December 31, 2024 (Unaudited) | December 31, 2025 (Unaudited) | December 31, 2024 (Unaudited) | March 31, 2025 (Audited) |
| A. | Continuing Operations | | | | | | |
| | Income | | | | | | |
| 1 | Revenue from operations | 2,902.20 | 3,751.87 | 3,367.49 | 9,864.19 | 8,221.75 | 12,995.89 |
| 2 | Other income | 46.24 | 30.36 | 59.06 | 129.15 | 137.73 | 176.82 |
| 3 | Total income (1+2) | 2,948.44 | 3,782.23 | 3,426.55 | 9,993.34 | 8,359.48 | 13,172.71 |
| 4 | Expenses | | | | | | |
| | (a) Cost of materials consumed | 489.16 | 652.17 | 761.23 | 1,649.81 | 2,355.78 | 3,301.74 |
| | (b) Changes in inventories of finished goods and work-in-progress | 66.41 | (100.59) | 75.07 | 15.19 | 115.16 | 26.11 |
| | (c) Consumables | 383.22 | 558.24 | 112.23 | 1,308.48 | 488.06 | 753.98 |
| | (d) Employee benefits expenses | 640.60 | 625.26 | 571.93 | 1,847.38 | 1,638.56 | 2,148.00 |
| | (e) Finance costs | 379.85 | 333.08 | 439.17 | 983.24 | 1,292.56 | 1,616.50 |
| | (f) Depreciation and amortisation expenses | 345.66 | 342.07 | 339.76 | 1,020.57 | 1,009.18 | 1,345.12 |
| | (g) Other expenses | 1,194.49 | 1,000.99 | 852.16 | 3,100.46 | 2,301.00 | 3,073.31 |
| | Total expenses (4) | 3,499.39 | 3,411.22 | 3,151.55 | 9,925.13 | 9,200.30 | 12,264.76 |
| 5 | Profit/(Loss) before exceptional items and tax (3-4) | (550.95) | 371.01 | 275.00 | 68.21 | (840.82) | 907.95 |
| 6 | Exceptional items - loss (net) (Refer note 5) | (70.90) | - | (1,005.23) | (70.90) | (1,122.50) | (1,122.50) |
| 7 | Profit/(Loss) before tax (5+6) | (621.85) | 371.01 | (730.23) | (2.69) | (1,963.32) | (214.55) |
| 8 | Income tax expense | | | | | | |
| | Current tax | - | - | - | - | - | - |
| | Deferred tax | - | - | - | - | (414.55) | (414.55) |
| | Total tax expense | - | - | - | - | (414.55) | (414.55) |
| 9 | Profit/(Loss) after tax (7-8) | (621.85) | 371.01 | (730.23) | (2.69) | (1,548.77) | 200.00 |
| B. | Discontinued Operations | | | | | | |
| | (i) Loss from Discontinued Operations (Refer note 3) | - | - | - | - | - | (6.90) |
| 10 | Profit/(Loss) after tax from discontinued operations | - | - | - | - | - | (6.90) |
| 11 | Profit/(Loss) for the period/year (9+10) | (621.85) | 371.01 | (730.23) | (2.69) | (1,548.77) | 193.10 |
| 12 | Other Comprehensive Income | | | | | | |
| | Items that will not be reclassified to statement of profit and loss | | | | | | |
| | - Remeasurements of post employment benefit obligations- gain/(loss) | 4.51 | - | - | 4.51 | (30.44) | (29.65) |
| | Total other comprehensive income/(loss) | 4.51 | - | - | 4.51 | (30.44) | (29.65) |
| 13 | Total comprehensive income/(loss) for the period/year (10+11) | (617.34) | 371.01 | (730.23) | 1.82 | (1,579.21) | 163.45 |
| 14 | Paid-up equity share capital (of Rs. 1/- each) | 114.58 | 114.52 | 114.43 | 114.58 | 114.43 | 114.43 |
| 15 | Reserves (Other Equity) | | | | | | 59,086.58 |
| 16 | Earnings/ (Loss) per share (of Rs. 1/- each) (for continuing operations): | (not annualised) | (not annualised) | (not annualised) | (not annualised) | (not annualised) | (annualised) |
| | - Basic | (5.43) | 3.24 | (6.69) | (0.02) | (14.20) | 1.81 |
| | - Diluted | (5.43) | 3.24 | (6.69) | (0.02) | (14.20) | 1.81 |
| | Earnings/ (Loss) per share (of Rs. 1/- each) (for discontinued operations): | | | | | | |
| | - Basic | - | - | - | - | - | (0.06) |
| | - Diluted | - | - | - | - | - | (0.06) |
| | Earnings/ (Loss) per share (of Rs. 1/- each) (for total operations): | | | | | | |
| | - Basic | (5.43) | 3.24 | (6.69) | (0.02) | (14.20) | 1.75 |
| | - Diluted | (5.43) | 3.24 | (6.69) | (0.02) | (14.20) | 1.75 |

See accompanying notes to the Statement of Unaudited Standalone Financial Results for the quarter and nine months ended December 31, 2025

Notes to the Statement of Unaudited Standalone Financial Results for the quarter and nine months ended December 31, 2025

1 In terms of Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015, ("Listing Requirements"), as amended, the Statement of Unaudited Standalone Financial Results for the quarter and nine months ended December 31, 2025 ("Statement") of OneSource Specialty Pharma Limited (formerly known as Stelis Biopharma Limited) ('the Company') has been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on January 23, 2026. The aforesaid results for the quarter and nine months ended December 31, 2025 has been reviewed by Deloitte Haskins & Sells, the statutory auditors of the Company, who have issued an unmodified conclusion in respect of the limited review for the quarter and nine months ended December 31, 2025.

2 The above Statement has been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013, as amended, read with relevant rules thereunder and in terms of Listing Requirements, as amended.

3 During the year ended March 31 2024, the Company entered into a Business Transfer Agreement with Syngene International Limited for sale of Unit-3 (multimodal facility) on a slump sale basis. During the quarter ended December 31, 2023, parties as per the BTA have completed the transaction related to divestment of Unit-3.

The Company has classified the Unit-3 multimodal facility related operations which is transferred by the Company to Syngene as discontinued operations in line with the requirements of Ind AS 105 - Non-current assets held for sale and discontinued operations.

Syngene withheld Rs. 100 million which is to be paid post completion of certain closing conditions. During the year ended March 31, 2024, the Management accounted for a provision of Rs. 50 million which was the Management's best estimate of the recoverability of the pending amount. During the previous year, the Company has received Rs. 43.10 million out of the retained amount and has accounted for an additional provision of Rs. 6.90 million and accordingly have disclosed under discontinued operations.

4 During the previous quarter, the Company has entered into Composite Scheme of Arrangement and Amalgamation (Merger by Absorption) amongst Steriscience Specialties Private Limited ('Transferor Company 1') and Brooks Steriscience Limited ('BSL' / 'Transferee Company 1' / 'Transferor Company 2') and Steriscience Pte Limited ('Steriscience SG' / 'Transferor Company 3') and Strides Pharma Services Private Limited ('SPSPL' / 'Transferor Company 4') and OneSource Specialty Pharma Limited (the 'Company'/'OneSource'/'Transferee Company 2') ("Composite Scheme"), wherein Brooks Steriscience Limited, Steriscience Pte Limited and Strides Pharma Services Private Limited, will be amalgamated with the Company and financial restructuring to set-off the negative balance in the Retained Earnings Account, against the balance lying in the Securities Premium Account.

Composite Scheme is approved by the Board of Directors in its meeting held on September 26, 2025. The Company is in the process of obtaining relevant regulatory approvals.

5 Exceptional items (net)

| Particulars | Rs. in Million | | | | | |
|--|-------------------|--------------------|-------------------|-------------------|-------------------|-----------------|
| | Quarter ended | | | Nine months ended | | Year ended |
| | December 31, 2025 | September 30, 2025 | December 31, 2024 | December 31, 2025 | December 31, 2024 | March 31, 2025 |
| Provision/(reversal) towards investment/trade receivables in subsidiaries/step-down subsidiary (net) | - | - | - | - | 14.05 | 14.05 |
| Business combination, listing and post-merger integration related expenses ¹ | - | - | 1,005.23 | - | 1,108.45 | 1,108.45 |
| Employees' one-time mutual separation settlement | 41.47 | - | - | 41.47 | - | - |
| Gratuity and Compensated absences impact under new Labour Codes | 29.43 | - | - | 29.43 | - | - |
| Total | 70.90 | - | 1,005.23 | 70.90 | 1,122.50 | 1,122.50 |

¹ Pertains to expenses incurred towards the Scheme of arrangement and consequent listing of the Company, expenses majorly includes legal and professional fees, provisional stamp duty expenses, one-time incentive and awards to employees and interest on prepayment of debt pursuant to the Scheme of arrangement.

6 The Company publishes these Unaudited Standalone Financial Results along with Unaudited Consolidated Financial Results. In accordance with Ind AS 108, 'Operating Segments', the Company has disclosed the segment information in the Unaudited Consolidated Financial Results.

7 Figures for the previous periods, wherever necessary have been regrouped/reclassified to confirm to the current period's presentation.

For and on behalf of Board of Directors of OneSource Specialty Pharma Limited (formerly known as Stelis Biopharma Limited)

NEERAJ SHARMA
Digitally signed by NEERAJ SHARMA
Date: 2026.01.23 19:04:54 +05'30'

Neeraj Sharma
Managing Director
DIN : 09402652

Place : Bengaluru
Date : January 23, 2026